公开(公告)号：US12195517B2

公开(公告)日：2025-01-14

申请号：US17280803

申请日：2019-06-12

Applicant: VACDIAGN BIOTECHNOLOGY CO., LTD

Inventor： Jianqing Xu ,  Yang Huang ,  Xiaoyan Zhang ,  Lu Wang ,  Mingquan Gao ,  Jiahao Sun

IPC: C07K14/73 ,  A61K39/00 ,  A61K39/02 ,  A61K39/12 ,  A61K39/145 ,  A61K39/245 ,  A61P31/04 ,  A61P31/16 ,  A61P31/20 ,  A61P31/22 ,  A61P35/00 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86

Abstract: The present invention provides a recombinant viral vector, an immunogenic composition containing the same, and the use thereof. The recombinant viral vector comprises a polynucleotide encoding a fusion peptide of CD4 helper T cell epitopes, the epitope fusion peptide comprising a cytomegalovirus epitope and/or an influenza virus epitope. The epitope fusion peptide and the recombinant viral vector provided by the present invention can improve the level of cellular immune response to a target immunogen, particularly to a weak immunogen, and overcome the immune tolerance of immune system to an antigen, particularly to a tumor antigen or an infection-related antigen. The products of the present invention are suitable for enhancing the efficacy of vaccines.

公开(公告)号：US20220002750A1

公开(公告)日：2022-01-06

申请号：US17280803

申请日：2019-06-12

Applicant: VACDIAGN BIOTECHNOLOGY CO., LTD

Inventor： Jianqing Xu ,  Yang Huang ,  Xiaoyan Zhang ,  Lu Wang ,  Mingquan Gao ,  Jiahao Sun

IPC: C12N15/86 ,  C07K14/73 ,  C07K14/005 ,  C12N7/00 ,  A61K39/00 ,  A61P31/04 ,  A61P35/00 ,  A61K39/145 ,  A61K39/245 ,  A61P31/16 ,  A61P31/20 ,  A61K39/02

Abstract: The present invention provides a recombinant viral vector, an immunogenic composition containing the same, and the use thereof. The recombinant viral vector comprises a polynucleotide encoding a fusion peptide of CD4 helper T cell epitopes, the epitope fusion peptide comprising a cytomegalovirus epitope and/or an influenza virus epitope. The epitope fusion peptide and the recombinant viral vector provided by the present invention can improve the level of cellular immune response to a target immunogen, particularly to a weak immunogen, and overcome the immune tolerance of immune system to an antigen, particularly to a tumor antigen or an infection-related antigen. The products of the present invention are suitable for enhancing the efficacy of vaccines.